[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Aura Biosciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100565569","phase-2-suprachoroidal-administration-in-subjects-with-metastases-to-the-choroid-100565569",false,"NCT06643884","Suprachoroidal Administration in Subjects With Metastases to the Choroid","A Phase 2, Open-Label, Dose Escalation Trial Assessing the Safety, Tolerability, and Treatment Effect of Belzupacap Sarotalocan (AU-011) With Suprachoroidal Administration in Subjects With Metastases to the Choroid","Inclusion Criteria:\n\n* Have a clinical diagnosis of Metastases to the Choroid, from a histopathologically or cytologically confirmed tumor.\n* Have at least one Metastases to the Choroid in the study eye\n\nExclusion Criteria:\n\n* Active ocular infection or disease.\n* Must not have evidence of a primary tumor or metastatic lesion in the brain requiring treatment with radiation therapy per the primary treating oncologist's assessment.\n* Must not be planning or expecting to switch\u002Fadd systemic antineoplastic therapies during treatment","ALL","18 Years",{"count":19,"type":20},24,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.",[26,27],"Eye Cancer","Primary Cancer",[29,30,31,32],"Choroidal Metastasis","Metastases to the Choroid","ocular","eye","RECRUITING","2026-03-11",{"date":36,"type":37},"2026-03-13","ACTUAL",{"date":39,"type":37},"2024-12-16",{"date":41,"type":20},"2027-10-31",{"name":43,"class":44},"Aura Biosciences","INDUSTRY",10,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100625369","choroidal-melanoma-patient-reported-outcome-study-cm-pro-in-a-subset-of-au-011-301-compass-subjects-100625369","NCT07421739","Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects","Inclusion Criteria:\n\n* Have enrolled in the Aura-sponsored clinical trial AU-011-301.\n* Access to a connected device (i.e., smartphone, laptop, or tablet)\n\nExclusion Criteria:\n\n* None",{"count":53,"type":20},15,"OBSERVATIONAL","To assess subject-centric real-world evidence of QoL outcomes in subjects enrolled in the global Phase 3 AU-011-301 clinical trial.",[57,58,59,60],"Choroidal Melanoma","Indeterminate Lesions","Uveal Melanoma","Ocular Melanoma",[59,26,60,57],"2026-02-17",{"date":64,"type":37},"2026-02-19",{"date":66,"type":37},"2025-11-12",{"date":68,"type":20},"2028-08-15",{"name":43,"class":44},1,""]